$SBFM Sunshine Biopharma Initiates COVID-19 Treatm
Post# of 42189
Press Release | 02/10/2021
MONTREAL, QC / ACCESSWIRE / February 10, 2021 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has initiated a momentous transgenic mice study of its COVID-19 treatment that has been under development since May of last year. Sunshine Biopharma's COVID-19 treatment consists of a series of small molecules which suppress replication of the virus by inhibiting a key virus encoded protease that is responsible for compromising the immune system of infected patients. The mice studies are currently underway at the University of Georgia, College of Pharmacy.
https://www.otcmarkets.com/stock/SBFM/news/Su...?id=289393
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.